Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Anacor Pharmaceuticals, Inc.Financial_Report.xls
EX-10.37 - EX-10.37 - Anacor Pharmaceuticals, Inc.a2223421zex-10_37.htm
EX-10.38 - EX-10.38 - Anacor Pharmaceuticals, Inc.a2223421zex-10_38.htm
EX-10.39 - EX-10.39 - Anacor Pharmaceuticals, Inc.a2223421zex-10_39.htm
EX-10.11 - EX-10.11 - Anacor Pharmaceuticals, Inc.a2223421zex-10_11.htm
EX-31.2 - EX-31.2 - Anacor Pharmaceuticals, Inc.a2223421zex-31_2.htm
EX-23.1 - EX-23.1 - Anacor Pharmaceuticals, Inc.a2223421zex-23_1.htm
EX-31.1 - EX-31.1 - Anacor Pharmaceuticals, Inc.a2223421zex-31_1.htm
10-K - 10-K - Anacor Pharmaceuticals, Inc.a2223421z10-k.htm
EX-4.8 - EX-4.8 - Anacor Pharmaceuticals, Inc.a2223421zex-4_8.htm

QuickLinks -- Click here to rapidly navigate through this document


Exhibit 32.1

CERTIFICATION

        Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Paul L. Berns, President and Chief Executive Officer of Anacor Pharmaceuticals, Inc. (the "Company"), and Geoffrey M. Parker, Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

    1.
    The Company's Annual Report on Form 10-K for the year ended December 31, 2014, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

    2.
    The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 16th day of March 2015.

/s/ PAUL L. BERNS

Paul L. Berns
President and Chief Executive Officer
  /s/ GEOFFREY M. PARKER

Geoffrey M. Parker
Executive Vice President and Chief Financial Officer

        A signed original of this written statement required by Rule 13a-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350) has been provided to Anacor Pharmaceuticals, Inc. and will be retained by Anacor Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

        This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Anacor Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Annual Report on Form 10-K), irrespective of any general incorporation language contained in such filing.




QuickLinks

CERTIFICATION